Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that explicitly targets enzymes responsible for inflammation and pain namely cyclooxygenase-2 and COX-2.
Some of the NSAIDs can be used in a single dose to treat various types of pain; it can also be used for post-surgical pains.

The global Etoricoxib Intermediate market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Etoricoxib Intermediate volume and value at global level, regional level and company level. From a global perspective, this report represents overall Etoricoxib Intermediate market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Etoricoxib Intermediate in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Etoricoxib Intermediate manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Bayer
Novacap
Abbott
Pfizer
Geri-Care
Perrigo
Kopran
Merck
Sun Pharmaceutical
GlaxoSmithKline

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
n-House Manufacturing
Contract Manufacturing Organizations

Segment by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Osteoarthritis
Ankylosing Spondylitis
Chronic Low Back Pain
Acute Pain
Others